Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been assigned a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and three have given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $110.5455.

A number of research analysts have recently weighed in on the company. Canaccord Genuity Group began coverage on Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 target price on the stock. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Wolfe Research initiated coverage on Structure Therapeutics in a research note on Thursday, March 26th. They set a “peer perform” rating on the stock. BMO Capital Markets set a $145.00 price objective on shares of Structure Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $53.36 on Monday. The stock has a market cap of $3.79 billion, a price-to-earnings ratio of -61.33 and a beta of -1.50. Structure Therapeutics has a fifty-two week low of $15.80 and a fifty-two week high of $94.90. The firm’s 50-day simple moving average is $43.44 and its 200 day simple moving average is $57.15.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. On average, sell-side analysts predict that Structure Therapeutics will post -1.64 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GPCR. Sterling Capital Management LLC bought a new stake in Structure Therapeutics in the 1st quarter worth about $28,000. State of Wyoming purchased a new stake in Structure Therapeutics in the 2nd quarter valued at about $28,000. CWM LLC lifted its position in shares of Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 125 shares in the last quarter. Assetmark Inc. lifted its position in shares of Structure Therapeutics by 21.4% during the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after buying an additional 449 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Structure Therapeutics in the 4th quarter worth approximately $127,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.